secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001193125-23-030087
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma posts net income of $10.3M; discontinues zandelisib development outside Japan
--------------------------------------------------------------------------------

- Net income of $10.3M ($0.08 per share) vs net loss of $12.2M in prior-year quarter.
- Revenue surged to $32.7M (up from $11.8M) driven by updated cost estimates on Kyowa Kirin license.
- Cash and investments $124.2M with no debt; cash used in operations $14.3M.
- Discontinued global development of zandelisib outside Japan; initiated workforce reduction.
- Pipeline narrowed to voruciclib (Phase 1b with venetoclax) and ME-344 (Phase 1 in colorectal cancer).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523030087/0001193125-23-030087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523030087/d387877d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-030087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer